| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 181,858 | $700,153 | $3.85 | 14 Aug 2025 | Direct |
| Aquestive Therapeutics, Inc. | Chief Commercial Officer | Non-Qualified Stock Option (right to buy) | 35,000 | 07 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | 14 Aug 2025 | 1 | $0 | 4 | Chief Commercial Officer | 15 Aug 2025, 08:41 |
| AQST | Aquestive Therapeutics, Inc. | 09 Jun 2025 | 1 | -$9,608 | 4 | SVP Sales and Marketing | 10 Jun 2025, 14:12 |
| AQST | Aquestive Therapeutics, Inc. | 07 Mar 2025 | 3 | -$14,384 | 4 | SVP Sales and Marketing | 11 Mar 2025, 17:48 |
| AQST | Aquestive Therapeutics, Inc. | 07 Jun 2024 | 1 | $0 | 4 | SVP Sales and Marketing | 11 Jun 2024, 12:36 |
| AQST | Aquestive Therapeutics, Inc. | 03 Jun 2024 | 0 | $0 | 3/A | SVP Sales and Marketing | 12 Jun 2024, 17:14 |
| AQST | Aquestive Therapeutics, Inc. | 03 Jun 2024 | 0 | $0 | 3 | SVP Sales and Marketing | 11 Jun 2024, 12:35 |